REVOLUTION MEDICINES INC

Revolution Medicines to unveil Phase‑1 data for its KRAS G12D inhibitor, zoldonrasib, at AACR 2026, promising a 50%+ ORR and 1‑year PFS in heavily pre‑treated NSCLC patients.

Revolution Medicines raises $2.2 billion via equity and convertible notes, funding RAS‑targeted oncology R&D and potential commercialization while maintaining investor confidence.